High density lipoprotein prevention

High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
High density lipoprotein prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of High density lipoprotein prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on High density lipoprotein prevention
CDC on High density lipoprotein prevention
High density lipoprotein prevention in the news
Blogs on High density lipoprotein prevention
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for High density lipoprotein prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]

Overview

Statins and fibrate appear to be effective in patients with low HDL levels compared to those in normal HDL levels in terms of risk reduction.Fibrates are more effective when low HDL levels coincide with low levels of LDL levels. Before a combination of statins and fibrates are considered, dietary modifications and lifestyle changes can be effective tools to raise HDL levels. However, a combination therapy of statins with fibrates can result in myopathy as a potential adverse effect.

Secondary Prevention

As of 2006, randomized clinical trials have demonstrated significant reduction of atherosclerosis progression and cardiovascular events with treatments that increase HDL-cholesterol (nicotinic acid or a fibrate). Pharmacological therapy to increase the level of HDL cholesterol includes use of fibrates and niacin. Consumption of niacin, an immediate release crystalline form of Vitamin B3, can increase HDL levels by 10–30%, and is the most powerful agent currently available to increase HDL-cholesterol. The use of statins is effective against high levels of LDL cholesterol, but it has little or no effect in raising HDL-cholesterol. The use of antioxidants in combination with statin and niacin therapy reduces the effectiveness of niacin by 33%. (NIH HATS).

Diet and Lifestyle

Certain changes in lifestyle can have a positive impact on raising HDL levels:

• Aerobic exercise
• Weight loss
• Smoking cessation
• Using supplements such as omega 3 fish oil
• Limiting intake of dietary fat to 30–35% of total calories
• Removing trans fatty acids from the diet
• Adding monounsaturated and polyunsaturated fats to the diet, and reducing or eliminating saturated fats.
• Drinking 1–2 servings of alcoholic beverages per day
• Adding soluble fiber to diet

Pharmacotherapy

Low HDL

Rule out secondary causes e.g., Hypothyroidism, diabetes mellitus, uremia, liver disease, Medications - diuretics, progestin, androgens, beta blockers, Acute illness - MI, burns, surgery

Lifestyle modification - Diet, physical exercise, smoking cessation, weight loss, Intake of unhydrogenated monounsaturated fat e.g., olive oil, canola oil

No Coronary heart disease

Assess risk

High risk CHD risk>20% per 10 years

Low risk CHD≤20% per 10 years

Statins or Niacin

Positive family history of premature CHD

Negative family history of premature CHD

Considar statins or niacin

Continue non-pharmacological approach

CETP Inhibition

Anacetrapib

Anacetrapib raises HDL by 138%, and lowers LDL by 35% to 40%.

Evacetrapib

Evacetrapib raises HDL by 130% and lowers LDL by 35% to 40%.

References

Template:WikiDoc Sources